| |
Agenda
Check this page for the latest program information. Speakers and their time slots are subject to change.
DIRECTIONS
Driving directions and a map of the campus can be found at http://www.hbs.edu/about/visit.html
THURSDAY
FRIDAY
SATURDAY
THURSDAY EVENING
NOVEMBER 3, 2005
4:00-8:00 PM Thursday
Williams Room Foyer, Spangler Center, HBS Campus
Check-In (Note: there is no on-site registration.)
5:00-6:00 PM Thursday
Spangler Auditorium
Opening Lecture
No Drug is Risk-Free: The FDA’s Response to the Crisis in the Pharmaceutical Industry
Janet Woodcock, MD
Acting Deputy Commissioner for Operations, US Food and Drug Administration
Washington, DC
The high out-of-pocket costs for medicines borne by some Americans, combined with widely publicized safety issues (and the perception that some safety problems have been concealed) have combined to create widespread anger and distrust directed towards the pharmaceutical industry. Basically, the public believes that the industry has placed its financial health ahead of the customers’ health. This situation is ironic since this industry has delivered major health benefits and remains the single most important mechanism for further progress in preventing and treating human disease.
This presentation will cover the factual basis underlying many of the conflicts and will suggest ways to forge a new consensus on medical product regulation.
6:00-8:30PM Thursday
Williams Room, Spangler Center
Welcome Reception and Dinner
In partnership with the students of HBS, HBS Healthcare Club
- Welcome Back to HBS
Robert DeNoble, MBA ’72
President, HBS Health Industry Alumni Association
- The Healthcare Initiative at Harvard Business School
Richard Hamermesh, MBA '71, DBA '76
Professor of Management Practice, Harvard Business School
At last year’s HBS Health Care Alumni Conference, Dean Clark announced the establishment of the HBS Healthcare Initiative. Professor Richard Hamermesh, Faculty Chair of the Initiative, will review the major elements of the Initiative. Professor Hamermesh will discuss the role HBS alumni can play in helping the Initiative to achieve its objectives.
•back to top
FRIDAY
NOVEMBER 4, 2005
8:00 AM -6:00 PM Friday
Williams Room Foyer, Spangler Center
Check-In (Note: there is no on-site registration.)
8:00 AM -8:45 AM Friday
Williams Room, Spangler Center
Continental Breakfast
9:00-9:15 AM Friday
Spangler Auditorium
Opening Remarks and Introduction
9:15-10:15 AM Friday
Spangler Auditorium
The U.S. Government's Strategic Framework for Improving Health Care Through Health Information Technology
David J. Brailer, MD, PhD
National Coordinator for Health Information Technology, Department of Health and Human Services, Washington, DC
In 2004, President George W. Bush appointed David Brailer, MD, PhD to the newly created position of The National Coordinator for Health Information Technology. The Office of the National Coordinator will collaborate with the public, private, and non-profit sectors to meet the President's goal of widespread adoption of interoperable electronic health records within 10 years.
Automation of the health care industry through widespread use of health information technology (HIT) offers a unique opportunity to improve quality and reduce costs at the same time. HIT is also critical to transforming how health care is delivered. Dr. Brailer will provide an update on the building blocks and the strategies that are under way to provide consumer-centric and information-rich health care.
•back to top
10:15-10:45 AM Friday
Coffee Break
10:45-Noon Friday
Spangler Auditorium
The State of Affairs in the Drug Developing Industry
Moderator: Scott Hensley
Staff Journalist, The Wall Street Journal
Panelists:
- Mark C. Fishman, MD
President, Novartis Institutes for Biomedical Research
- Jerome P. Kassirer, MD
Distinguished Professor, Tufts University School of Medicine; Professor (Adjunct) of Medicine and Bioethics, Case Western Reserve University; Editor-in-Chief Emeritus, New England Journal of Medicine
- Josef H. von Rickenbach, MBA '81
Founder, Chairman, and CEO, PAREXEL International Corporation
- Una Ryan, PhD
CEO, Avant Immunotherapeutics, Inc.; Chairman, The Massachusetts Biotechnology Council
This session will investigate evolving trends in the biotechnology and pharmaceutical industries. Panelists represent frequent rivals increasingly intertwined as biotechnology firms challenge the laboratories of established drug makers and academia as the prime source of new medicines.
In recent years, the largest drug makers have been unable to replenish their product portfolios alone, fueling talk of an innovation deficit in Big Pharma. Biotechnology firms argue they are the true innovators. But biotechnology firms often fail in drug development, testing investors' patience. Established drug makers argue that research is cyclical, and that their huge investments will pay off. Further, the biggest companies argue that scale is necessary to harness the latest science and to see drugs through clinical testing to market.
Factor in a third player: government, which oversees the development and marketing of drugs. Governments also participate as both financiers for research and purchasers of its fruit, new medicines, diagnostic tests and vaccines.
And as the recent crisis around the withdrawal of several blockbuster drugs from the market showed, the public often blames industry and government equally when things go wrong. Consumer advocates question whether regulatory agencies, such as the FDA, are capable of protecting patients' health.
Pointed questions from the media about the safety of antidepressants and misguided accusations that Eli Lilly suppressed information led to an apology from the British Journal of Medicine, demonstrating that the media are important, but sometimes flawed, participants in the debate.
What are the proper roles and relationships among the players in this vital field?
Noon-1:15 PM Friday
Williams Room, Spangler Center
Luncheon, concurrent with Deans' Address:
Two Months After the Launch of the MD-MBA Curriculum: First Retrospective
1:15-2:15 PM Friday
Spangler Auditorium
Genzyme's Position in the State of Affairs of the Drug Developing Industry
Earl M. Collier, Jr.
Executive Vice President, Genzyme Corporation
Genzyme has matured from a biotechnology company into a drug company without losing its dynamic spirit. It has strengthened its global infrastructure for product development and manufacturing through major expansion projects, particularly in areas of antibody and protein-based medicines. Genzyme has never pursued the blockbuster-based strategy of the traditional pharmaceutical industry, but gained scientific market leadership with several specialty products for niche indications. This presentation will discuss Genzyme's Ilex acquisition and its strategy in the oncology market, the complementary relationship with Genzyme Mol Diagnostics for the development of therapeutics, and strategies for pipeline development. Genzyme has to face the crisis as any other member of the drug developing value chain, but has developed a unique strategy that seems to adapt well to industry change.
•back to top
2:15-2:30 PM Friday
Break 2:30-3:45 PM Friday
Spangler Auditorium
International Financing Session
From IP to IPO:
A European Perspective for the Life Sciences
Moderator: Christoph von Arb, PhD
Consul General of Switzerland and Director, Swiss House for Advanced Research and Education (SHARE), Cambridge, MA
Panelists:
- Paula Cobb, MBA '00
Director, Commercial Operations, Biogen Idec International
- Marcus Sasse, MD
Senior Healthcare Analyst and Strategist, UBS Global Asset Management, Zurich, Switzerland
- Ronald Scott
CFO, Basilea Pharmaceutica, Basel, Switzerland
- Andreas Wicki, PhD
CEO, HBM BioVentures AG, Zug, Switzerland
The European Union (EU) encompasses a market of 380 million people with a mature healthcare and life sciences industry. Even though Switzerland is not a member of the EU, the country is extremely well linked with it through a series of bilateral agreements covering all important fields of international relations. This is vital for Switzerland. Since the domestic market is limited, its industry and commerce depend heavily on exports which in turn has created an investor-friendly climate and favorable framework conditions for foreign companies. Currently, also a Free Trade Agreement with the United States is under negotiation. An important factor of an increasingly knowledge-based industry is the availability of resources and infrastructure for Research and Education. Both have tradition in Switzerland, which is home to some of the biggest chemical and pharmaceutical companies. Switzerland is not only a full member of the multibillion EU-Framework Program in RTD which grants it full access to all the projects, partners and results of the program, but it also invests heavily into targeted areas such as Life Sciences and Nanotechnology. Swiss banks and finance industries are adding their part to a vibrant and expanding life sciences industry. These efforts have helped Switzerland emerge as a prime Life Science Location in Europe. Some have recently called it the "Massachusetts of Europe." The ingredients are all there. A closer look will confirm that Switzerland is ready to tackle the challenges of a globalized economy. The first country to approve stem cell research by popular vote in 2004 is proof of a pragmatic Switzerland.
3:45-4:00 PM Friday
Break 4:00-5:00 PM Friday
Spangler Auditorium
Saving Dollars by Simplifying Healthcare - $1 Billion at a Time
William Jessee, MD, FACMPE, FACPM
President and CEO, Medical Group Management Association (MGMA)
The US system for financing and administering healthcare services is rife with unnecessary administrative complexity and redundancy. This complexity creates frustration for all parties and has created adversarial relationships between purchasers and providers. As much as $300 billion per year could potentially be saved by simplifying and streamlining administrative processes. This presentation will present data on the cost of a variety of administrative processes, and describe savings that could be generated through standardization and simplification of those processes.
•back to top
5:00-6:00 PM Friday
Spangler Auditorium
The Evolution of Medical Devices
Stephen N. Oesterle, MD
Senior Vice President for Medicine and Technology, Medtronic, Inc.
6:00-9:00 PM Friday
Williams Room, Spangler Center
Cocktails and Dinner on HBS Campus
- Honoring Bunny Ellerin, MBA ’95
Founder, Past President and Chairman of HBS Health Industry Alumni Association
Presentation by Robert DeNoble, MBA '72
President, HBS Health Industry Alumni Association
- Dinner Presentation: How to Raise $200 Million in 180 Days
Kenneth A. Abramowitz, MBA '76
NGN Capital (New Global Network
This talk will focus on future trends in healthcare delivery, and of the challenges of investing in venture capital focused on medical device and pharma companies in order to create value and accelerate product development. It will concentrate on how to improve the investment process by pursuing products/services/companies most capable of improving quality while lowering costs. Armed with an improved investment process and a strong investment team, fund managers can then face the challenges inherent in raising $200 million in 18 months. Different strategies are required to raise funds from the diverse array of targeted investors: fund-of-fund investors, government pension funds, corporate pension funds, corporate investors, high net worth investors, friends and family.
•back to top
SATURDAY
NOVEMBER 5, 2005
8:30-10:00 AM Saturday
Faculty Club, Kresge
Check-In (Note: there is no on-site registration.)
8:30-9:45 AM Saturday
Faculty Club, Kresge
Breakfast Roundtable Discussions
Chair: David P. Terry, MBA '98
Vice President, HBS Health Industry Alumni Association
Attendees will choose roundtables according to their areas of interest, and will discuss a specific healthcare topic over breakfast.
10:00-11:15 AM Saturday
Burden Auditorium
Redefining Health Care: Creating Value-Based Competition on Results
Michael E. Porter, PhD, MBA '71
University Professor, Harvard Business School
Professor Porter will describe the crisis of the U.S. health care system, providing insights into the underlying causes of the problem and a prescription for change. To date, the participants in the health care system have competed to shift costs, accumulate bargaining power, and restrict services, rather than create value for patients. This zero-sum competition currently takes place at the wrong level--among health plans, networks, and hospitals--rather than in the diagnosis, treatment, management, and prevention of specific health conditions (where it matters most). Redefining Health Care lays out a framework for health care competition based on patient value.
11:30-12:45 PM Saturday
Aldrich 112
HBS Case Study: GlaxoSmithKline: Reorganizing Drug Discovery
Led by Robert S. Huckman, PhD
Assistant Professor, Harvard Business School
This case-based discussion will examine the reorganization of drug discovery at GlaxoSmithKline (GSK) following the formation of GSK from the merger of Glaxo Wellcome and SmithKline Beecham. This reorganization placed nearly 2,000 research scientists into six centers of excellence in drug discovery (CEDD). Each CEDD focused on a small set of therapeutic areas and possessed decision rights over the progression of pharmaceutical compounds through the early stages of development. This session will address the issues GSK faced in designing the CEDD structure.
1:00-2:15 PM Saturday
Faculty Club, Kresge
Luncheon & Closing Remarks
Robert DeNoble, MBA '72
President, HBS Health Industry Alumni Association
•back to top
©2005 Harvard Business School Health Industry Alumni Association.
All rights reserved. |
